RecruitingNCT07288567
KarXT for schizophrenia in adolescents aged 13 to 17
About this title
Read the official source — NCT07288567Researchers are comparing KarXT and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Medication studyAges 13–17Multiple countries
Understand this study
What is this study about?
Researchers are comparing KarXT and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria apply.
- Listed locations
- Anaheim and 36 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: January 29, 2026
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 166
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug, OTHER
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, Colombia, Japan, ...
- Age range
- From 13 Years to 17 Years
- Official registry ID
- NCT07288567
- Official title
Show the full official title
A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (13 to 17 Years of Age)
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Anaheim, United States · Chino, United States · Culver City, United States
31 more locations
- San Francisco, United States
- Hollywood, United States
- Orlando, United States
- Atlanta, United States
- Lawrenceville, United States
- Stone Mountain, United States
- Chicago, United States
- Boston, United States
- Worcester, United States
- Great Neck, United States
- Cincinnati, United States
- Nashville, United States
- Garland, United States
- Houston, United States
- Spring, United States
- Richmond, United States
- Bello, Colombia
- Pereira, Colombia
- Barranquilla, Colombia
- Chikugo-Shi, Japan
- Sapporo, Japan
- Zentsujichó, Japan
- Miyakonojō, Japan
- Bunkyo-ku, Japan
- Ōta-ku, Japan
- Yokohama, Kanagawa, Japan
- Bucharest, Romania
- Cluj-Napoca, Romania
- Iași, Romania
- Sibiu, Romania
- Timișoara, Romania
Questions about this study
What is this study about?
Researchers are comparing KarXT and placebo to find out how the approaches affect psychotic symptoms in young people with schizophrenia.
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including KarXT.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 13 years to 17 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
Want to explore more studies?
Explore studiesRelated studies
Long-term safety of LB-102 in adults with schizophrenia
A double blind, randomized, placebo-controlled, adaptive 24-week Phase IIb trial to evaluate the efficacy of vafidemstat in negative symptoms and cognitive impairment associated with schizophrenia....